Identification and pharmacological characterization of platelet- activating factor and related 1-palmitoyl species in human inflammatory blistering diseases

Jeffrey B. Travers, Robert C. Murphy, Christopher A. Johnson, Pei Yong, S. Michelle Morin, Keith L. Clay, Lisa A. Barber, Antoinette F. Hood, Joseph G. Morelli, David A. Williams

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Through its pro-inflammatory effects on leukocytes, endothelial cells, and keratinocytes, the lipid mediator platelet-activating factor (PAF) has been implicated in cutaneous inflammation. Although the 1-alkyl PAF species has been considered historically the most abundant and important ligand for the PAF receptor (PAF-R), other putative ligands for this receptor have been described including 1-acyl analogs of sn-2 acetyl glycerophosphocholines. Previous bioassays have demonstrated a PAF-like activity in lesions of the autoimmune blistering disease bullous pemphigoid. To assess the actual sn-2 acetyl glycerophosphocholine species that result in this PAF agonistic activity, we measured PAF and related sn-2 acetyl GPCs in fresh blister fluid samples from bullous pemphigoid and noninflammatory (suction-induced) bullae by mass spectrometry. We report the presence of 1-hexadecyl as well as the 1- acyl PAF analog 1-palmitoyl-2-acetyl glycerophosphocholine (PAPC) in inflammatory blister fluid samples. Because PAPC is the most abundant sn-2 acetyl glycerophosphocholine species found in all samples examined, the pharmacological effects of this species with respect to the PAF-R were determined using a model system created by transduction of a PAF-R-negative epidermoid cell line with the PAF-R. Radioligand binding and intracellular calcium mobilization studies indicated that PAPC is approximately 100X less potent than PAF. Though a weak agonist, PAPC could induce PAF biosynthesis and PAF-R desensitization. Finally, intradermal injections of PAF and PAPC into the ventral ears of rats demonstrated that PAPC was 100X less potent in vivo. These studies suggest possible involvement of PAF and related species in inflammatory bullous diseases.

Original languageEnglish
Pages (from-to)305-324
Number of pages20
JournalProstaglandins and Other Lipid Mediators
Volume56
Issue number5-6
DOIs
StatePublished - 1998

Fingerprint

Platelet Activating Factor
Pharmacology
Blister
Bullous Pemphigoid
Ligands
Intradermal Injections
Fluids
Bioassay
Biosynthesis
Endothelial cells
Suction
Keratinocytes
Biological Assay
Autoimmune Diseases
Mass spectrometry
Ear
1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine
Rats
Mass Spectrometry
Leukocytes

Keywords

  • Bullous pemphigoid
  • Human
  • Platelet-activating factor
  • Rat
  • Skin
  • Wistar

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Identification and pharmacological characterization of platelet- activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. / Travers, Jeffrey B.; Murphy, Robert C.; Johnson, Christopher A.; Yong, Pei; Morin, S. Michelle; Clay, Keith L.; Barber, Lisa A.; Hood, Antoinette F.; Morelli, Joseph G.; Williams, David A.

In: Prostaglandins and Other Lipid Mediators, Vol. 56, No. 5-6, 01.12.1998, p. 305-324.

Research output: Contribution to journalArticle

Travers, Jeffrey B. ; Murphy, Robert C. ; Johnson, Christopher A. ; Yong, Pei ; Morin, S. Michelle ; Clay, Keith L. ; Barber, Lisa A. ; Hood, Antoinette F. ; Morelli, Joseph G. ; Williams, David A. / Identification and pharmacological characterization of platelet- activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. In: Prostaglandins and Other Lipid Mediators. 1998 ; Vol. 56, No. 5-6. pp. 305-324.
@article{8ec6e35e13394d149aba7a939e975cb5,
title = "Identification and pharmacological characterization of platelet- activating factor and related 1-palmitoyl species in human inflammatory blistering diseases",
abstract = "Through its pro-inflammatory effects on leukocytes, endothelial cells, and keratinocytes, the lipid mediator platelet-activating factor (PAF) has been implicated in cutaneous inflammation. Although the 1-alkyl PAF species has been considered historically the most abundant and important ligand for the PAF receptor (PAF-R), other putative ligands for this receptor have been described including 1-acyl analogs of sn-2 acetyl glycerophosphocholines. Previous bioassays have demonstrated a PAF-like activity in lesions of the autoimmune blistering disease bullous pemphigoid. To assess the actual sn-2 acetyl glycerophosphocholine species that result in this PAF agonistic activity, we measured PAF and related sn-2 acetyl GPCs in fresh blister fluid samples from bullous pemphigoid and noninflammatory (suction-induced) bullae by mass spectrometry. We report the presence of 1-hexadecyl as well as the 1- acyl PAF analog 1-palmitoyl-2-acetyl glycerophosphocholine (PAPC) in inflammatory blister fluid samples. Because PAPC is the most abundant sn-2 acetyl glycerophosphocholine species found in all samples examined, the pharmacological effects of this species with respect to the PAF-R were determined using a model system created by transduction of a PAF-R-negative epidermoid cell line with the PAF-R. Radioligand binding and intracellular calcium mobilization studies indicated that PAPC is approximately 100X less potent than PAF. Though a weak agonist, PAPC could induce PAF biosynthesis and PAF-R desensitization. Finally, intradermal injections of PAF and PAPC into the ventral ears of rats demonstrated that PAPC was 100X less potent in vivo. These studies suggest possible involvement of PAF and related species in inflammatory bullous diseases.",
keywords = "Bullous pemphigoid, Human, Platelet-activating factor, Rat, Skin, Wistar",
author = "Travers, {Jeffrey B.} and Murphy, {Robert C.} and Johnson, {Christopher A.} and Pei Yong and Morin, {S. Michelle} and Clay, {Keith L.} and Barber, {Lisa A.} and Hood, {Antoinette F.} and Morelli, {Joseph G.} and Williams, {David A.}",
year = "1998",
month = "12",
day = "1",
doi = "10.1016/S0090-6980(98)00060-4",
language = "English (US)",
volume = "56",
pages = "305--324",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "5-6",

}

TY - JOUR

T1 - Identification and pharmacological characterization of platelet- activating factor and related 1-palmitoyl species in human inflammatory blistering diseases

AU - Travers, Jeffrey B.

AU - Murphy, Robert C.

AU - Johnson, Christopher A.

AU - Yong, Pei

AU - Morin, S. Michelle

AU - Clay, Keith L.

AU - Barber, Lisa A.

AU - Hood, Antoinette F.

AU - Morelli, Joseph G.

AU - Williams, David A.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Through its pro-inflammatory effects on leukocytes, endothelial cells, and keratinocytes, the lipid mediator platelet-activating factor (PAF) has been implicated in cutaneous inflammation. Although the 1-alkyl PAF species has been considered historically the most abundant and important ligand for the PAF receptor (PAF-R), other putative ligands for this receptor have been described including 1-acyl analogs of sn-2 acetyl glycerophosphocholines. Previous bioassays have demonstrated a PAF-like activity in lesions of the autoimmune blistering disease bullous pemphigoid. To assess the actual sn-2 acetyl glycerophosphocholine species that result in this PAF agonistic activity, we measured PAF and related sn-2 acetyl GPCs in fresh blister fluid samples from bullous pemphigoid and noninflammatory (suction-induced) bullae by mass spectrometry. We report the presence of 1-hexadecyl as well as the 1- acyl PAF analog 1-palmitoyl-2-acetyl glycerophosphocholine (PAPC) in inflammatory blister fluid samples. Because PAPC is the most abundant sn-2 acetyl glycerophosphocholine species found in all samples examined, the pharmacological effects of this species with respect to the PAF-R were determined using a model system created by transduction of a PAF-R-negative epidermoid cell line with the PAF-R. Radioligand binding and intracellular calcium mobilization studies indicated that PAPC is approximately 100X less potent than PAF. Though a weak agonist, PAPC could induce PAF biosynthesis and PAF-R desensitization. Finally, intradermal injections of PAF and PAPC into the ventral ears of rats demonstrated that PAPC was 100X less potent in vivo. These studies suggest possible involvement of PAF and related species in inflammatory bullous diseases.

AB - Through its pro-inflammatory effects on leukocytes, endothelial cells, and keratinocytes, the lipid mediator platelet-activating factor (PAF) has been implicated in cutaneous inflammation. Although the 1-alkyl PAF species has been considered historically the most abundant and important ligand for the PAF receptor (PAF-R), other putative ligands for this receptor have been described including 1-acyl analogs of sn-2 acetyl glycerophosphocholines. Previous bioassays have demonstrated a PAF-like activity in lesions of the autoimmune blistering disease bullous pemphigoid. To assess the actual sn-2 acetyl glycerophosphocholine species that result in this PAF agonistic activity, we measured PAF and related sn-2 acetyl GPCs in fresh blister fluid samples from bullous pemphigoid and noninflammatory (suction-induced) bullae by mass spectrometry. We report the presence of 1-hexadecyl as well as the 1- acyl PAF analog 1-palmitoyl-2-acetyl glycerophosphocholine (PAPC) in inflammatory blister fluid samples. Because PAPC is the most abundant sn-2 acetyl glycerophosphocholine species found in all samples examined, the pharmacological effects of this species with respect to the PAF-R were determined using a model system created by transduction of a PAF-R-negative epidermoid cell line with the PAF-R. Radioligand binding and intracellular calcium mobilization studies indicated that PAPC is approximately 100X less potent than PAF. Though a weak agonist, PAPC could induce PAF biosynthesis and PAF-R desensitization. Finally, intradermal injections of PAF and PAPC into the ventral ears of rats demonstrated that PAPC was 100X less potent in vivo. These studies suggest possible involvement of PAF and related species in inflammatory bullous diseases.

KW - Bullous pemphigoid

KW - Human

KW - Platelet-activating factor

KW - Rat

KW - Skin

KW - Wistar

UR - http://www.scopus.com/inward/record.url?scp=0039229380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0039229380&partnerID=8YFLogxK

U2 - 10.1016/S0090-6980(98)00060-4

DO - 10.1016/S0090-6980(98)00060-4

M3 - Article

C2 - 9990675

AN - SCOPUS:0039229380

VL - 56

SP - 305

EP - 324

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 5-6

ER -